BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 31276980)

  • 1. The A.L.A.N. score identifies prognostic classes in advanced biliary cancer patients receiving first-line chemotherapy.
    Salati M; Caputo F; Cunningham D; Marcheselli L; Spallanzani A; Rimini M; Gelsomino F; Reggiani-Bonetti L; Andrikou K; Rovinelli F; Smyth E; Baratelli C; Kouvelakis K; Kalaitzaki R; Gillbanks A; Michalarea V; Cascinu S; Braconi C
    Eur J Cancer; 2019 Aug; 117():84-90. PubMed ID: 31276980
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Derived neutrophil lymphocyte ratio may predict benefit from cisplatin in the advanced biliary cancer: the ABC-02 and BT-22 studies.
    Grenader T; Nash S; Plotkin Y; Furuse J; Mizuno N; Okusaka T; Wasan H; Valle J; Bridgewater J
    Ann Oncol; 2015 Sep; 26(9):1910-1916. PubMed ID: 26037798
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognostic and predictive factors for Taiwanese patients with advanced biliary tract cancer undergoing frontline chemotherapy with gemcitabine and cisplatin: a real-world experience.
    Wu CE; Chou WC; Hsieh CH; Chang JW; Lin CY; Yeh CN; Chen JS
    BMC Cancer; 2020 May; 20(1):422. PubMed ID: 32410631
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In Gastric Cancer Patients Receiving Neoadjuvant Chemotherapy Systemic Inflammation Response Index is a Useful Prognostic Indicator.
    Chen L; Chen Y; Zhang L; Xue Y; Zhang S; Li X; Song H
    Pathol Oncol Res; 2021; 27():1609811. PubMed ID: 34712105
    [No Abstract]   [Full Text] [Related]  

  • 5. Predictive factors of the treatment outcome in patients with advanced biliary tract cancer receiving gemcitabine plus cisplatin as first-line chemotherapy.
    Suzuki Y; Kan M; Kimura G; Umemoto K; Watanabe K; Sasaki M; Takahashi H; Hashimoto Y; Imaoka H; Ohno I; Mitsunaga S; Ikeda M
    J Gastroenterol; 2019 Mar; 54(3):281-290. PubMed ID: 30298469
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio, and their dynamic changes during chemotherapy is useful to predict a more accurate prognosis of advanced biliary tract cancer.
    Cho KM; Park H; Oh DY; Kim TY; Lee KH; Han SW; Im SA; Kim TY; Bang YJ
    Oncotarget; 2017 Jan; 8(2):2329-2341. PubMed ID: 27911876
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cisplatin and gemcitabine in patients with advanced biliary tract cancer (ABC) and persistent jaundice despite optimal stenting: Effective intervention in patients with luminal disease.
    Lamarca A; Benafif S; Ross P; Bridgewater J; Valle JW
    Eur J Cancer; 2015 Sep; 51(13):1694-703. PubMed ID: 26066735
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A prognostic model in patients with advanced biliary tract cancer receiving first-line chemotherapy.
    Filippi R; Montagnani F; Lombardi P; Fornaro L; Aprile G; Casadei-Gardini A; Faloppi L; Palloni A; Satolli MA; Scartozzi M; Citarella F; Lutrino SE; Vivaldi C; Silvestris N; Rovesti G; Rimini M; Aglietta M; Brandi G; Leone F
    Acta Oncol; 2021 Oct; 60(10):1317-1324. PubMed ID: 34282710
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Blood neutrophil-lymphocyte ratio predicts survival for stages III-IV gastric cancer treated with neoadjuvant chemotherapy.
    Jin H; Zhang G; Liu X; Liu X; Chen C; Yu H; Huang X; Zhang Q; Yu J
    World J Surg Oncol; 2013 May; 11():112. PubMed ID: 23705622
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An inflammation-based cumulative prognostic score system in patients with diffuse large B cell lymphoma in rituximab era.
    Sun F; Zhu J; Lu S; Zhen Z; Wang J; Huang J; Ding Z; Zeng M; Sun X
    BMC Cancer; 2018 Jan; 18(1):5. PubMed ID: 29291712
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Neutrophil/lymphocyte ratio as a prognostic factor in biliary tract cancer.
    McNamara MG; Templeton AJ; Maganti M; Walter T; Horgan AM; McKeever L; Min T; Amir E; Knox JJ
    Eur J Cancer; 2014 Jun; 50(9):1581-9. PubMed ID: 24630393
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Second-line chemotherapy in advanced biliary cancers: A retrospective, multicenter analysis of outcomes.
    Lowery MA; Goff LW; Keenan BP; Jordan E; Wang R; Bocobo AG; Chou JF; O'Reilly EM; Harding JJ; Kemeny N; Capanu M; Griffin AC; McGuire J; Venook AP; Abou-Alfa GK; Kelley RK
    Cancer; 2019 Dec; 125(24):4426-4434. PubMed ID: 31454426
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Neutrophil count and the inflammation-based glasgow prognostic score predict survival in patients with advanced gastric cancer receiving first-line chemotherapy.
    Li QQ; Lu ZH; Yang L; Lu M; Zhang XT; Li J; Zhou J; Wang XC; Gong JF; Gao J; Li J; Li Y; Shen L
    Asian Pac J Cancer Prev; 2014; 15(2):945-50. PubMed ID: 24568523
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic value of pre-treatment Naples prognostic score (NPS) in patients with osteosarcoma.
    Yang Q; Chen T; Yao Z; Zhang X
    World J Surg Oncol; 2020 Jan; 18(1):24. PubMed ID: 32000789
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Advanced Intrahepatic Cholangiocarcinoma: Post Hoc Analysis of the ABC-01, -02, and -03 Clinical Trials.
    Lamarca A; Ross P; Wasan HS; Hubner RA; McNamara MG; Lopes A; Manoharan P; Palmer D; Bridgewater J; Valle JW
    J Natl Cancer Inst; 2020 Feb; 112(2):200-210. PubMed ID: 31077311
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Outcome and patterns of care in advanced biliary tract carcinoma (ABC): experience from two tertiary institutions in the United Kingdom.
    Huggett MT; Passant H; Hurt C; Pereira SP; Bridgewater J; Mukherjee S
    Tumori; 2014; 100(2):219-24. PubMed ID: 24852869
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hemoglobin and Neutrophil Count as Prognostic Factors in Cholangiocarcinoma Patients in 2nd Line Treatment Setting: Results from a Small Monocentric Retrospective Study.
    Liguori C; Copparoni C; Felicetti C; Pecci F; Lupi A; Pinterpe G; Berardi R; Giampieri R
    Curr Oncol; 2023 Jan; 30(1):1032-1045. PubMed ID: 36661728
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prediction of survival with second-line therapy in biliary tract cancer: Actualisation of the AGEO CT2BIL cohort and European multicentre validations.
    Neuzillet C; Casadei Gardini A; Brieau B; Vivaldi C; Smolenschi C; Brandi G; Tougeron D; Filippi R; Vienot A; Silvestris N; Pointet AL; Lonardi S; Rousseau B; Scartozzi M; Dahan L; Aprile G; Boussaha T; Malka D; Crusz SM; Le Sourd S; Meurisse A; Lièvre A; Vernerey D; ; ; ;
    Eur J Cancer; 2019 Apr; 111():94-106. PubMed ID: 30826661
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Third-line chemotherapy in advanced biliary cancers (ABC): pattern of care, treatment outcome and prognostic factors from a multicenter study.
    Salati M; Rizzo A; Merz V; Messina C; Francesco C; Gelsomino F; Spallanzani A; Ricci AD; Palloni A; Frega G; De Lorenzo S; Carotenuto P; Pettorelli E; Benatti S; Luppi G; Melisi D; Brandi G; Dominici M
    Expert Rev Gastroenterol Hepatol; 2022 Jan; 16(1):73-79. PubMed ID: 34890512
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic Role of a New Index Tested in European and Korean Advanced Biliary Tract Cancer Patients: the PECS Index.
    Rovesti G; Leone F; Brandi G; Fornaro L; Scartozzi M; Niger M; Yoo C; Caputo F; Filippi R; Casagrande M; Silvestris N; Santini D; Faloppi L; Palloni A; Aglietta M; Vivaldi C; Cho H; Lai E; Fenocchio E; Nichetti F; Pella N; De Lorenzo S; Di Maio M; Vasile E; de Braud F; Jeong JH; Aprile G; Orsi G; Cascinu S; Casadei-Gardini A
    J Gastrointest Cancer; 2022 Jun; 53(2):289-298. PubMed ID: 33544375
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.